J2G-MC-JZJC - ClinicalTrials.gov - NCT04194944
J2G-MC-JZJC - ClinicalTrials.gov - NCT04194944
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) that cannot be treated with surgery or radiation therapy
Participants must have a RET gene fusion and sufficient tumor tissue available for confirmatory testing
Participants must be in fair to good health and not have another serious medical condition
Participants must not have had prior chemotherapy for metastatic lung cancer. Chemotherapy in the adjuvant/neoadjuvant setting is permitted
Participants must not have disease that has spread to the brain and is causing symptoms
Participants must be able to swallow capsules
Participants must be willing to use highly effective contraception during the study
Participants must NOT
Participants must not have a heart condition that puts you at risk for abnormal heart rhythms
Trial Summary
Conditions the trial is for
Non-small Cell Lung Cancer
What the trial is testing?
Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Could I receive a Placebo?
no
Enrollment Goal
250
Trial Dates
February 2020 - August 2025
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) that cannot be treated with surgery or radiation therapy
Participants must have a RET gene fusion and sufficient tumor tissue available for confirmatory testing
Participants must be in fair to good health and not have another serious medical condition
Participants must not have had prior chemotherapy for metastatic lung cancer. Chemotherapy in the adjuvant/neoadjuvant setting is permitted
Participants must not have disease that has spread to the brain and is causing symptoms
Participants must be able to swallow capsules
Participants must be willing to use highly effective contraception during the study
Participants must NOT
Participants must not have a heart condition that puts you at risk for abnormal heart rhythms
Trial Summary
Conditions the trial is for
Non-small Cell Lung Cancer
What the trial is testing?
Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Could I receive a Placebo?
no
Enrollment Goal
250
Trial Dates
February 2020 - August 2025
Trial Phase
3
Trial Locations
Hide locations not currently recruiting